Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.
- Trial name
- NCT01392469
- Testing
- Imatinib, Sildenafil, Bosentan
- Where
- 11 sites in United States, Australia and 5 more
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension (PAH)
Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by increased pressure in the pulmonary arteries, leading to right heart failure and premature death.
- Trial name
- ASCEND-PAH (NCT07713914)
- Testing
- Prostacyclin Pathway Agent, Sildenafil Dose Optimization
- Where
- Brazil
- Volunteers
- 196 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension
FUTURE 3 Study Extension
The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension…
- Trial name
- FUTURE 3 Ext (NCT01338415)
- Testing
- Bosentan
- Where
- 36 sites in United States, Australia and 16 more
- Volunteers
- 58 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
PET Image in PAH Patients
Pulmonary arterial hypertension (PAH) is mortal disease affecting the blood vessels of the lung. Despite its morbid prognosis, PAH is often misdiagnosed or ignored, with an average time of 44 months between onset of symptoms to…
- Trial name
- NCT05452889
- Testing
- 18F-FGLN PET Imaging, (18F)FPGLU
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Stephen Y. Chan
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
- Trial name
- ROCSTAR (NCT07175038)
- Testing
- ROC-101
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AllRock Bio, Inc.
Pulmonary Arterial Hypertension
To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers
The purpose of this study is to compare the pharmacokinetics of two Traclear 62.5 mg tablets and one HGP1206 125 mg tablet in healthy male volunteers.
- Trial name
- NCT01864863
- Testing
- HGP1206, Traclear
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Pulmonary Arterial Hypertension
Bosentan in Children With Pulmonary Arterial Hypertension
The aim of the study is to demonstrate that the exposure to bosentan in children with idiopathic pulmonary arterial hypertension (PAH) or familial pulmonary arterial hypertension, using a pediatric formulation, is similar to that…
- Trial name
- FUTURE-1 (NCT00319267)
- Testing
- Bosentan
- Volunteers
- 36 people
- Sponsor
- Actelion
Sleep-Disordered Breathing, Pulmonary Arterial Hypertension
Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment
Evaluation of the effect of CPAP (continuous positive airway pressure ) treatment in PAH (pulmonary arterial hypertension) and CTEPH (chronic thromboembolic pulmonary hypertension) patients suffering from sleep disordered…
- Conditions
- Sleep-Disordered Breathing, Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT02583906
- Testing
- CPAP
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Lung Hypoxia, Pulmonary Arterial Hypertension
Iron Status and Hypoxic Pulmonary Vascular Responses
On exposure to hypoxia (low oxygen) the normal response is for pulmonary arterial systolic blood pressure (PASP, blood pressure through the lungs) to increase.
- Conditions
- Lung Hypoxia, Pulmonary Arterial Hypertension, Iron Deficiency
- Trial name
- NCT01847352
- Testing
- Intravenous administration of ferric carboxymaltose, Subacute hypoxic exposures
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pulmonary Artery Hypertension, Right Ventricular Dysfunction
Right Ventricular Pacing in Pulmonary Arterial Hypertension
In pulmonary arterial hypertension (PAH), progressive pulmonary vascular remodeling leads to supraphysiologic right ventricular (RV) afterload.
- Trial name
- NCT04194632
- Testing
- Temporary right ventricular pacing
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension
A Mobile Health Intervention in Pulmonary Arterial Hypertension
This study proposes the use of a mobile health intervention (utilizing a smart phone app) to encourage increased exercise in PAH patients.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Associated Pulmonary Arterial Hypertension
- Trial name
- mHealth (NCT03069716)
- Testing
- Smartphone Text Messaging, Fitbit Charge HR
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension, Scleroderma
Novel Screening Strategies for Scleroderma PAH
Patients with scleroderma can develop heart failure due to high blood pressure in the lungs (a condition called pulmonary arterial hypertension).
- Trial name
- NCT01959815
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease
An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The purpose of this study is to provide continued access to TPIP for participants who have successfully completed the open-label extension (OLE) studies of INS1009-203 for PAH or INS1009-212 for PH-ILD.
- Trial name
- NCT06939647
- Testing
- Treprostinil Palmitil
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension
Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)
Patients with pulmonary arterial hypertension (PAH) are at much higher risk of death if the RV (right ventricle) is weak. The purpose of this study is to get a better understanding of the factors that determine RV adaptation and…
- Trial name
- ISS (NCT02074449)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Arizona
Pulmonary Arterial Hypertension
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
The goal of this clinical trial is to evaluate the capacity of implantable/remote technology for early evaluation of drug therapies in patients with pulmonary arterial hypertension (PAH).
- Trial name
- PHoenix (NCT05825417)
- Testing
- Selexipag, Riociguat, CardioMEMS pulmonary artery pressure monitor
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Anxiety Self-management Intervention for Pulmonary Hypertension
Pulmonary hypertension (PH) is a disorder of high blood pressure that impacts the heart and lungs. Approximately, 50% of individuals with PH experience anxiety or panic disorders.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Anxiety, Anxiety Disorders
- Trial name
- NCT04450862
- Testing
- Cognitive Behavioural therapy self help intervention for anxiety
- Where
- 2 sites in United Kingdom
- Volunteers
- 64 people
- Sponsor
- University of Sheffield
High Altitude, Healthy
Assessment of Total Pulmonary Resistance sPAP/CO Between Sea Level LA vs. High Altitude HA After Re-ascent in Healthy Individuals
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy…
- Conditions
- High Altitude, Healthy, Healthy Adult, High Altitude Effects
- Trial name
- NCT07804589
- Testing
- Re-Ascent from sea level to 2850m
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Lung Diseases, Hypertension, Pulmonary
Genetic and Environmental Characteristics of Primary Pulmonary Hypertension
The goal of this study is to identify the modifying genes and environmental features that regulate the clinical expression of mutations in bone morphogenetic protein receptor 2 (BMPR2); to develop the understanding of how BMPR2…
- Trial name
- NCT00091546
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Vanderbilt University
Pulmonary Arterial Hypertension
Inhaled Treprostinil for PAH: Open-label Extension
Open-label extension of RIN-PH-302.
- Trial name
- INTREPID - OL (NCT01557660)
- Testing
- inhaled treprostinil
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
Efficacy and Safety of Ambrisentan in Children 8-18yrs
A 6-month (24-week), randomized, open label evaluation of the safety, tolerability, and efficacy of a high and low dose ambrisentan (adjusted for body weight) treatment group in subjects aged 8 years up to 18 years with pulmonary…
- Trial name
- NCT01332331
- Testing
- Ambrisentan - low dose, Ambrisentan - high dose
- Where
- 24 sites in United States, Argentina and 7 more
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline